Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05868356 · ClinicalTrials.gov registry record · Phase 1
A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05868356 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT05868356, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
A Phase 1, Open-label, Multiple-dose, One-sequence Crossover Study to Investigate the Effect of Repeated Oral Doses of a Strong CYP2C8 Inhibitor on the Steady-state Pharmacokinetics of Adagrasib in Healthy Adult Subjects
Interventions
- DRUG Treatment A
- DRUG Treatment B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2023-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05868356
The ClinicalTrials.gov registry entry for NCT05868356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment A is the first listed.
NCT05868356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05868356 about?
NCT05868356 is a clinical study titled "A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib". A Phase 1, Open-label, Multiple-dose, One-sequence Crossover Study to Investigate the Effect of Repeated Oral Doses of a Strong CYP2C8 Inhibitor on the Steady-state Pharmacokinetics of Adagrasib in Healthy Adult Subjects
What is the current status of trial NCT05868356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-06-01. Estimated completion is 2023-08-07.
What interventions are being tested in trial NCT05868356?
The interventions under investigation include: Treatment A (DRUG), Treatment B (DRUG).
Who is sponsoring clinical trial NCT05868356?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.